Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...

Twenty states (plus D.C.) had "very high" levels of the virus present in wastewater, an increase from 16 states the week before.

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ability to invade human cells. SARS-CoV-2 is the virus that spreads COVID-19.

A new study published in the Journal of General Internal Medicine, “Incidence and Prevalence of Post‑COVID‑19 Myalgic ...

The National Institute of Mental Health has awarded a significant grant of $1.5 million to Jianyang Du, PhD, of the ...

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postac ...